Incyte Days Payable

: 313.17 (As of Jun. 2022)

View and export this data going back to 1993. Start your Free Trial

Incyte's average Accounts Payable for the three months ended in Jun. 2022 was $174 Mil. Incyte's Cost of Goods Sold for the three months ended in Jun. 2022 was $51 Mil. Hence, Incyte's Days Payable for the three months ended in Jun. 2022 was 313.17.

The historical rank and industry rank for Incyte's Days Payable or its related term are showing as below:

INCY' s Days Payable Range Over the Past 10 Years
Min: 253.55 Med: 332 Max: 33593.95
Current: 311.81

During the past 13 years, Incyte's highest Days Payable was 33593.95. The lowest was 253.55. And the median was 332.00.

INCY's Days Payable is ranked better than
69.64% of 685 companies
in the Biotechnology industry
Industry Median: 128.99 vs INCY: 311.81

Incyte's Days Payable increased from Jun. 2021 (248.73) to Jun. 2022 (313.17). It may suggest that Incyte delayed paying its suppliers.

Incyte Days Payable Historical Data

The historical data trend for Incyte's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Days Payable

328.98

332.53

299.47

253.55

327.38

Incyte Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Days Payable																248.73	270.56	297.88	347.71	313.17

Competitive Comparison

For the Biotechnology subindustry, Incyte's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Incyte Days Payable Distribution

For the Biotechnology industry and Healthcare sector, Incyte's Days Payable distribution charts can be found below:

* The bar in red indicates where Incyte's Days Payable falls into.

Incyte Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Incyte's Days Payable for the fiscal year that ended in Dec. 2021 is calculated as

	Days Payable (A: Dec. 2021 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2020 )	+	Accounts Payable (A: Dec. 2021 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2021 )	*	Days in Period
=	( (98.767	+	172.11)	/	2 )	/	151	*	365
=	135.4385					/	151	*	365
=	327.38

Incyte's Days Payable for the quarter that ended in Jun. 2022 is calculated as:

	Days Payable (Q: Jun. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2022 )	+	Accounts Payable (Q: Jun. 2022 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2022 )	*	Days in Period
=	( (152.547	+	194.77)	/	2 )	/	50.6	*	365 / 4
=	173.6585					/	50.6	*	365 / 4
=	313.17

Incyte Days Payable Related Terms

Thank you for viewing the detailed overview of Incyte's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (NAS:INCY) » Definitions » Days Payable

Comparable Companies

NAS:ALNY NAS:BMRN NAS:RPRX NAS:TECH NAS:UTHR NYSE:BHVN NAS:JAZZ NAS:SRPT NAS:LEGN NAS:HALO OCSE:NOVO B ASX:CSL NAS:VRTX NAS:MRNA NAS:REGN XKRX:207940 NAS:BNTX HKSE:02269 NAS:SGEN OCSE:GMAB

Traded in Other Exchanges

INCY:Mexico 0J9P:UK ICY:Germany ICY:Germany I1NC34:Brazil INCY:Austria

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Executives

Tray Thomas	officer: Principal Accounting Officer	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Brawley Otis W	director	5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518
High Katherine A	director	3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Harrigan Edmund	director
Morrissey Michael James	officer: EVP, Head of Tech. Operations	IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Dickinson Jonathan Elliott	officer: EVP, General Manager, Europe	CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Stamoulis Christiana	officer: EVP & Chief Financial Officer	C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139
Dhanak Dashyant	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Pasquale Maria E	officer: EVP & General Counsel	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Fouse Jacqualyn A	director	C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108
Iyengar Vijay K	officer: EVP GPS, BD, & Licensing	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Stein Steven H	officer: EVP & Chief Medical Officer	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Trower Paul	officer: VP, Finance & Prin Acc Officer	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Clancy Paul J	director	C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Bienaime Jean Jacques	director	925 PAGE MILL ROAD PALO ALTO CA 94304